Ironwood Pharmaceuticals, Inc. IRWD

IRWD Company Overview

Ironwood Pharmaceuticals, Inc. is a U.S.-based gastrointestinal (GI) healthcare company focused on the development and commercialization of therapies for GI and related disorders. The company operates primarily within the biopharmaceutical industry, with a strategic emphasis on diseases affecting the digestive system. Ironwood’s principal revenue driver has historically been LINZESS (linaclotide), a prescription therapy approved in the United States for adults with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). The company generates revenue primarily through collaboration arrangements, royalty income, and product-related partnerships associated with LINZESS and its broader GI portfolio.

Ironwood was founded in 1998 and was formerly known as Microbia, Inc. before adopting its current name. Over time, the company evolved from a broader biotechnology research platform into a more focused GI therapeutics company. Its strategic positioning has centered on leveraging commercial GI expertise, physician relationships, and established infrastructure in specialty and primary care markets. The company has also pursued pipeline expansion into abdominal pain and visceral hypersensitivity-related conditions, seeking to diversify beyond its reliance on LINZESS-related revenues.